Carpmaels & Ransford LLP
Client SatisfactionRecommended for its ‘strong industry knowledge’, Carpmaels & Ransford LLP is well-known for its ability to advise healthcare and life sciences clients in EPO oppositions, strategic prosecutions, and patent and SPC litigation. The practice is jointly led by David Wilson, who is entrusted by science and technology players to assist with multi-jurisdictional litigation, Hugh Goodfellow, and Jake Marshall, who helms the transactional group with his expertise in IP and technology. Other key names to note in the practice include Camilla Balleny, who is well-versed in patent litigation as well as advisory work, and Ian Kirby, whose arsenal of skills encompass monoclonal antibodies and voice recognition technologies, among others. Jennifer Antcliff enjoys considerable litigation experience, having represented clients in the High Court, Court of Appeal, and Supreme Court. Craig Lumb is also recommended.
Testimonials
Collated independently by Legal 500 research team.
‘The Carpmaels team has strong industry knowledge and does a great job integrating litigators with the patent attorney team.’
- 'David Wilson is a strong leader.’
- 'Very well-supported IP team with the patent prosecution back up.'
- 'Ian Kirby is an excellent leader.'
Key clients
- Sanofi-Aventis
- Johnson & Johnson group
- FibroGen, Inc.
- Novartis
- AMO Development, LLC
- Takeda
- Regeneron Pharmaceuticals, Inc.
- Bristol Myers Squibb
- Sidley Austin
Work highlights
- Representing Sanofi & Regeneron and Amgen in handling a long-running project involving EPO patent prosecution, EPO oppositions, national litigation support, and most recently UPC litigation relating Sanofi & Regeneron's Praluent® anti-PCSK9 antibody product and Amgen's competing Repatha® product.
- Representing Johnson & Johnson in defending and enforcing its patents that protect their biggest product, Stelara, which is a biological product used in the treatment of autoimmune diseases.
- Assisting Janssen with the revocation of certain antibody patents owned by Amgen at the EPO and in the UK, to clear the way for the launch of its product, TECVAYLI, Janssen’s first-in-class bispecific antibody therapy for treating multiple myeloma, an incurable blood cancer.
Lawyers
Practice head
The lawyer(s) leading their teams.
David Wilson, Hugh Goodfellow, Jake Marshall